Effects of Pitavastatin-NP on RISK pathway.

(A), Western blot analysis of phosphorylated Akt (Ser 473) in IR myocardium 3 hours after reperfusion. N = 6 per group. Data are compared using one-way ANOVA followed by Dunnett’s multiple comparison tests. (B), Western blot analysis of phosphorylated Akt in IR myocardium from animals treated with WM or with WM plus pitavastatin-NP, 3 hours after reperfusion. Data are mean±SEM (n = 6 per group) (C) Western blot analysis of phosphorylated Akt in IR myocardium from animals treated with FITC-NP or with pitavastatin-NP, 15 and 30 minutes after reperfusion. (D), Representative photomicrographs of IR areas of hearts treated with FITC-NP (left) and Pitavastatin-NP (middle and right) stained immunohistochemically with antibody against phospho-Akt, and an expanded view of the boxed area of the middle panel (right). Scale bar: 100 μm. (E), Western blot analysis of phosphorylated GSK3β (S9A) in IR myocardium 3 hours after reperfusion. N = 6 per group. Data are compared using one-way ANOVA followed by Dunnett’s multiple comparison tests.